Table 4.
Patient Satisfaction with Fentanyl Pectin Nasal Spray During Radiotherapy – Total Weekly Assessments of Patients for Treated BTcP Episodes in the Previous 24 Hours
| Total | |
|---|---|
| Positive assessmenta of FPNS efficacy, n (%) | N=120 |
| No | 32 (26.7) |
| Yes | 88 (73.3) |
| 95% CI | 65.4–81.2 |
| Positive assessmenta of FPNS tolerability, n (%) | N=115 |
| No | 15 (13.0) |
| Yes | 100 (87.0) |
| 95% CI | 80.8–93.1 |
| Positive assessmenta of FPNS ease of use, n (%) | N=119 |
| No | 15 (12.6) |
| Yes | 104 (87.4) |
| 95% CI | 81.4–93.4 |
Notes: aPositive assessment: patient “satisfied” or “very satisfied” on the weekly evaluation.
Abbreviations: BTcP, breakthrough cancer pain; CI, Confidence Interval; FPNS, fentanyl pectin nasal spray.